Alefacept

BreastfeedingPediatric
  • TRADE NAME: Amevive (Astellas)
  • INDICATIONS: Chronic plaque psoriasis (in adults)
  • CLASS: Immunosuppressant
  • HALF-LIFE: 270 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alcohol, BCG Vaccine, Echinacea, Leflunomide, Live vaccines, Natalizumab, Pimecrolimus, Sipuleucel-T, Tacrolimus, Trastuzumab

PREGNANCY CATEGORY: B

Contra-indicated in patients with HIV.

Our database has 35 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top